| Year |
Citation |
Score |
| 2023 |
Goldman MD, Chen S, Motl R, Pearsall R, Oh U, Brenton JN. Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis. Frontiers in Neurology. 14: 1259413. PMID 37859654 DOI: 10.3389/fneur.2023.1259413 |
0.395 |
|
| 2022 |
Brenton JN, Florenzo B, Koshiya H, Min S, Woolbright E, Coleman R, Chen S, Goldman M. Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis. Neurology. PMID 35985830 DOI: 10.1212/WNL.0000000000201098 |
0.402 |
|
| 2022 |
Ward M, Goldman MD. Epidemiology and Pathophysiology of Multiple Sclerosis. Continuum (Minneapolis, Minn.). 28: 988-1005. PMID 35938654 DOI: 10.1212/CON.0000000000001136 |
0.389 |
|
| 2021 |
Griffith NC, Hill BK, Goldman MD, Tingen SR. Evaluation of Treatment Practices for Urinalyses and Urine Cultures at an Outpatient Multiple Sclerosis Clinic. International Journal of Ms Care. 23: 234-238. PMID 34720764 DOI: 10.7224/1537-2073.2021-034 |
0.348 |
|
| 2021 |
Chen S, Sierra S, Shin Y, Goldman MD. Gait Speed Trajectory During the Six-Minute Walk Test in Multiple Sclerosis: A Measure of Walking Endurance. Frontiers in Neurology. 12: 698599. PMID 34381416 DOI: 10.3389/fneur.2021.698599 |
0.397 |
|
| 2019 |
Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS, Jacobs A, Kapoor R, Matthews PM, Mowry EM, Balcer LJ, Panzara M, Phillips G, Uitdehaag BMJ, Cohen JA, et al. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology. PMID 31641014 DOI: 10.1212/WNL.0000000000008519 |
0.387 |
|
| 2019 |
Brenton JN, Banwell B, Bergqvist AGC, Lehner-Gulotta D, Gampper L, Leytham E, Coleman R, Goldman MD. Pilot study of a ketogenic diet in relapsing-remitting MS. Neurology(R) Neuroimmunology & Neuroinflammation. 6: e565. PMID 31089482 DOI: 10.1212/Nxi.0000000000000565 |
0.45 |
|
| 2019 |
Brenton JN, Koshiya H, Woolbright E, Goldman MD. The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 5: 2055217319846141. PMID 31065380 DOI: 10.1177/2055217319846141 |
0.376 |
|
| 2019 |
Brenton JN, Woolbright E, Briscoe-Abath C, Qureshi A, Conaway M, Goldman MD. Body mass index trajectories in pediatric multiple sclerosis. Developmental Medicine and Child Neurology. PMID 30950520 DOI: 10.1111/dmcn.14233 |
0.352 |
|
| 2019 |
Lapides DA, Batchala PP, Donahue JH, Lisak RP, Meltzer EI, Narayan RN, Nath A, Frohman TC, Costello K, Goldman MD, Zamvil SS, Frohman EM. Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurology(R) Neuroimmunology & Neuroinflammation. 6: e546. PMID 30882020 DOI: 10.1212/NXI.0000000000000546 |
0.4 |
|
| 2019 |
Brenton J, Banwell B, Bergqvist C, Lehner-Gulotta D, Leytham E, Gampper L, Goldman M, Coleman R. Application of a Modified Ketogenic Diet in Relapsing-Remitting Multiple Sclerosis Subjects Journal of the Academy of Nutrition and Dietetics. 119. DOI: 10.1016/J.Jand.2019.06.069 |
0.368 |
|
| 2018 |
Waubant E, Amezcua L, Sicotte N, Hellwig K, Krupp L, Weinstock-Guttman B, Yeh A, Lucas RM, Longbrake EE, Yadav V, Rensel M, Mar S, Hersh C, Block V, Zipp F, ... ... Goldman MD, et al. Gender Inequities in the Multiple Sclerosis Community: A Call for Action Annals of Neurology. 84: 958-959. PMID 30387521 DOI: 10.1002/Ana.25359 |
0.324 |
|
| 2018 |
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, ... ... Goldman MD, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. The New England Journal of Medicine. 379: 846-855. PMID 30157388 DOI: 10.1056/Nejmoa1803583 |
0.367 |
|
| 2018 |
Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 4: 2055217318783766. PMID 30090638 DOI: 10.1177/2055217318783766 |
0.351 |
|
| 2018 |
Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 4: 2055217318776990. PMID 29796290 DOI: 10.1177/2055217318776990 |
0.315 |
|
| 2018 |
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet. Neurology. PMID 29545067 DOI: 10.1016/S1474-4422(18)30069-3 |
0.43 |
|
| 2018 |
Dandu SR, Engelhard MM, Qureshi A, Gong J, Lach JC, Brandt-Pearce M, Goldman MD. Understanding the Physiological Significance of Four Inertial Gait Features in Multiple Sclerosis. Ieee Journal of Biomedical and Health Informatics. 22: 40-46. PMID 29300700 DOI: 10.1109/Jbhi.2017.2773629 |
0.414 |
|
| 2017 |
Engelhard MM, Patek SD, Lach JC, Goldman MD. Real-world walking in multiple sclerosis: Separating capacity from behavior. Gait & Posture. 59: 211-216. PMID 29078135 DOI: 10.1016/J.Gaitpost.2017.10.015 |
0.443 |
|
| 2017 |
Brenton JN, Engel CE, Sohn MW, Goldman MD. Breastfeeding During Infancy Is Associated With a Lower Future Risk of Pediatric Multiple Sclerosis. Pediatric Neurology. PMID 29074058 DOI: 10.1016/j.pediatrneurol.2017.09.007 |
0.421 |
|
| 2017 |
LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, ... ... Goldman MD, et al. The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517723718. PMID 28799444 DOI: 10.1177/1352458517723718 |
0.491 |
|
| 2017 |
Goldman MD, Koenig S, Engel C, McCartney CR, Sohn MW. Glucocorticoid-associated blood glucose response and MS relapse recovery. Neurology(R) Neuroimmunology & Neuroinflammation. 4: e378. PMID 28761902 DOI: 10.1212/NXI.0000000000000378 |
0.386 |
|
| 2017 |
Engelhard MM, Patek SD, Sheridan K, Lach JC, Goldman MD. Remotely engaged: Lessons from remote monitoring in multiple sclerosis. International Journal of Medical Informatics. 100: 26-31. PMID 28241935 DOI: 10.1016/J.Ijmedinf.2017.01.006 |
0.463 |
|
| 2016 |
Qureshi A, Brandt-Pearce M, Goldman MD. Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk test. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2016: 4959-4962. PMID 28269381 DOI: 10.1109/EMBC.2016.7591840 |
0.422 |
|
| 2016 |
Qureshi A, Brandt-Pearce M, Goldman MD, Qureshi A, Brandt-Pearce M, Goldman MD, Qureshi A, Goldman MD, Brandt-Pearce M. Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk test. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2016: 4959-4962. PMID 28227624 DOI: 10.1109/EMBC.2016.7591840 |
0.422 |
|
| 2016 |
Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27903937 DOI: 10.1177/1352458516680749 |
0.462 |
|
| 2016 |
Ward MD, Jones DE, Goldman MD. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. Multiple Sclerosis and Related Disorders. 9: 47-49. PMID 27645342 DOI: 10.1016/j.msard.2016.06.007 |
0.399 |
|
| 2016 |
Cincotta MC, Engelhard MM, Stankey M, Goldman MD. Fatigue and fluid hydration status in multiple sclerosis: A hypothesis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27542703 DOI: 10.1177/1352458516663854 |
0.444 |
|
| 2016 |
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismyth R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, ... ... Goldman M, et al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials. PMID 27521810 DOI: 10.1016/J.Cct.2016.08.009 |
0.437 |
|
| 2016 |
Engelhard MM, Dandu SR, Patek SD, Lach JC, Goldman MD. Quantifying six-minute walk induced gait deterioration with inertial sensors in multiple sclerosis subjects. Gait & Posture. 49: 340-345. PMID 27479220 DOI: 10.1016/J.Gaitpost.2016.07.184 |
0.462 |
|
| 2016 |
Brenton JN, Goldman MD. A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosis. Multiple Sclerosis and Related Disorders. 8: 54-7. PMID 27456874 DOI: 10.1016/j.msard.2016.04.009 |
0.458 |
|
| 2016 |
Gong J, Qi Y, Goldman M, Lach J. Causality Analysis of Inertial Body Sensors for Multiple Sclerosis Diagnostic Enhancement. Ieee Journal of Biomedical and Health Informatics. PMID 27411232 DOI: 10.1109/Jbhi.2016.2589902 |
0.439 |
|
| 2016 |
Engelhard MM, Schmidt KM, Engel CE, Brenton JN, Patek SD, Goldman MD. The e-MSWS-12: improving the multiple sclerosis walking scale using item response theory. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. PMID 27342237 DOI: 10.1007/S11136-016-1342-2 |
0.429 |
|
| 2016 |
Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27003945 DOI: 10.1177/1352458516638941 |
0.43 |
|
| 2015 |
Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ. Effects of Dalfampridine Extended-Release Tablets on 6-Minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial. Clinical Therapeutics. PMID 26565077 DOI: 10.1016/J.Clinthera.2015.10.014 |
0.407 |
|
| 2015 |
Goldman MD, Stüve O. Smoking Beyond Multiple Sclerosis Diagnosis: A Risk Factor Still Worth Modifying. Jama Neurology. 72: 1105-6. PMID 26348489 DOI: 10.1001/jamaneurol.2015.1805 |
0.379 |
|
| 2015 |
Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR, Blight AR, Carrazana EJ. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. International Journal of Ms Care. 17: 138-45. PMID 26052259 DOI: 10.7224/1537-2073.2014-040 |
0.305 |
|
| 2015 |
Goldman MD, Naismith RT. Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits. Neurology. 84: 864-5. PMID 25636716 DOI: 10.1212/WNL.0000000000001319 |
0.353 |
|
| 2014 |
Jones DE, Goldman MD. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. Expert Review of Clinical Immunology. 10: 1281-91. PMID 25148422 DOI: 10.1586/1744666X.2014.951332 |
0.472 |
|
| 2014 |
Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opinion On Drug Safety. 13: 989-98. PMID 24935480 DOI: 10.1517/14740338.2014.920820 |
0.455 |
|
| 2013 |
Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 81: 1856-63. PMID 24174581 DOI: 10.1212/01.Wnl.0000436065.97642.D2 |
0.477 |
|
| 2013 |
Motl RW, Pilutti LA, Learmonth YC, Goldman MD, Brown T. Clinical importance of steps taken per day among persons with multiple sclerosis. Plos One. 8: e73247. PMID 24023843 DOI: 10.1371/Journal.Pone.0073247 |
0.426 |
|
| 2012 |
Motl RW, Suh Y, Balantrapu S, Sandroff BM, Sosnoff JJ, Pula J, Goldman MD, Fernhall B. Evidence for the different physiological significance of the 6- and 2-minute walk tests in multiple sclerosis. Bmc Neurology. 12: 6. PMID 22380843 DOI: 10.1186/1471-2377-12-6 |
0.47 |
|
| 2011 |
Marrie RA, Goldman M. Validation of the NARCOMS Registry: Tremor and Coordination Scale. International Journal of Ms Care. 13: 114-20. PMID 24453714 DOI: 10.7224/1537-2073-13.3.114 |
0.415 |
|
| 2011 |
Motl RW, Goldman M. Physical inactivity, neurological disability, and cardiorespiratory fitness in multiple sclerosis. Acta Neurologica Scandinavica. 123: 98-104. PMID 21108624 DOI: 10.1111/j.1600-0404.2010.01361.x |
0.456 |
|
| 2011 |
Motl RW, Suh Y, Dlugonski D, Weikert M, Agiovlasitis S, Fernhall B, Goldman M. Oxygen cost of treadmill and over-ground walking in mildly disabled persons with multiple sclerosis. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 32: 255-62. PMID 20798968 DOI: 10.1007/S10072-010-0396-0 |
0.418 |
|
| 2010 |
Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders. 3: 229-39. PMID 21179614 DOI: 10.1177/1756285610374117 |
0.461 |
|
| 2010 |
Motl RW, Goldman MD, Benedict RH. Walking impairment in patients with multiple sclerosis: exercise training as a treatment option. Neuropsychiatric Disease and Treatment. 6: 767-74. PMID 21173883 DOI: 10.2147/NDT.S10480 |
0.446 |
|
| 2010 |
Motl RW, Dlugonski D, Suh Y, Weikert M, Fernhall B, Goldman M. Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 91: 1942-7. PMID 21112438 DOI: 10.1016/J.Apmr.2010.08.011 |
0.441 |
|
| 2010 |
Motl RW, Sosnoff JJ, Dlugonski D, Suh Y, Goldman M. Does a waist-worn accelerometer capture intra- and inter-person variation in walking behavior among persons with multiple sclerosis? Medical Engineering & Physics. 32: 1224-8. PMID 20875952 DOI: 10.1016/J.Medengphy.2010.08.015 |
0.38 |
|
| 2010 |
Sosnoff JJ, Goldman MD, Motl RW. Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 868-77. PMID 20534642 DOI: 10.1177/1352458510373111 |
0.39 |
|
| 2010 |
Motl RW, Dlugonski D, Suh Y, Weikert M, Agiovlasitis S, Fernhall B, Goldman M. Multiple Sclerosis Walking Scale-12 and oxygen cost of walking. Gait & Posture. 31: 506-10. PMID 20226676 DOI: 10.1016/J.Gaitpost.2010.02.011 |
0.376 |
|
| 2008 |
Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 383-90. PMID 17942508 DOI: 10.1177/1352458507082607 |
0.478 |
|
| 2007 |
Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis Multiple Sclerosis. 13: 1176-1182. PMID 17623733 DOI: 10.1177/1352458507078388 |
0.388 |
|
| 2006 |
Goldman MD, Cohen JA, Fox RJ, Bethoux FA. Multiple sclerosis: treating symptoms, and other general medical issues. Cleveland Clinic Journal of Medicine. 73: 177-86. PMID 16478042 DOI: 10.3949/ccjm.73.2.177 |
0.338 |
|
| 2006 |
Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleveland Clinic Journal of Medicine. 73: 91-102. PMID 16444920 DOI: 10.3949/CCJM.73.1.91 |
0.315 |
|
| 1998 |
Schneider JE, Goldman MD, Tang S, Bean B, Ji H, Friedman MI. Leptin indirectly affects estrous cycles by increasing metabolic fuel oxidation. Hormones and Behavior. 33: 217-28. PMID 9698504 DOI: 10.1006/Hbeh.1998.1453 |
0.405 |
|
| 1997 |
Schneider JE, Goldman MD, Leo NA, Rosen ME. Central vs. peripheral metabolic control of estrous cycles in Syrian hamsters. II. Glucoprivation. The American Journal of Physiology. 272: R406-12. PMID 9039036 |
0.399 |
|
| Show low-probability matches. |